Rapamycin · comparison
Rapamycin vs metformin for longevity compared
Rapamycin and metformin are the two most-discussed longevity drugs. They are often pitted against each other, but they are really answering different questions.
This is a comparison, not a competition. The two drugs differ in mechanism, in the type of evidence behind them, and in who might reasonably consider them. For the deeper single-drug picture, see the main rapamycin guide and our overview of metformin for longevity — both part of the Rapamycin.store library.
How do they work differently?
The mechanisms are genuinely distinct. Rapamycin directly inhibits mTOR, the cell's growth switch, pushing cells toward repair and recycling.[1] Metformin acts mainly on metabolism — improving insulin sensitivity and influencing energy-sensing pathways such as AMPK — rather than inhibiting mTOR head-on.[3] They approach ageing from different angles.
Which has the stronger evidence?
It depends on what kind of evidence you weigh. Rapamycin has the more striking animal result: it extended lifespan in genetically diverse mice even when started in mid-life.[2] Metformin's case leans on human epidemiology and long clinical experience, which is the rationale behind the proposed TAME (Targeting Aging with Metformin) trial.[3] Strong mouse data versus long human data is the core trade-off.
No proven human lifespan benefit for eitherWhat are the notable downsides?
Each drug carries its own caveats. Rapamycin is an immunosuppressant with dose-dependent side effects that longevity dosing tries to minimise.[1] Metformin has a well-known catch for active people: one study found it blunted some mitochondrial adaptations to aerobic exercise in older adults, which complicates its use in those who exercise heavily.[4] Neither is a free lunch.
Who might consider which?
There is no formula here, and this is not personal advice. Broadly, the debate weighs rapamycin's mechanistic and animal strength against metformin's human track record and metabolic focus — while remembering the exercise trade-off. Because both are prescription drugs, the choice, if any, is one to make with a clinician who knows your health.
The honest bottom line
Both drugs are serious, both are unproven for human longevity, and both are prescription-only. Anyone framing one as a clear anti-ageing winner is getting ahead of the evidence. Treat them as two different research bets, not a ranking.
Frequently asked questions
Is rapamycin or metformin better for longevity?
Neither is proven to extend human lifespan, so there is no clear winner. Rapamycin has stronger animal lifespan data; metformin has decades of human safety experience and supportive epidemiology. They work by different mechanisms and are studied for different reasons.
How do rapamycin and metformin differ in mechanism?
Rapamycin directly inhibits the mTOR growth pathway. Metformin works mainly on metabolism — improving insulin sensitivity and influencing energy-sensing pathways such as AMPK — rather than by inhibiting mTOR directly.
Can you take rapamycin and metformin together?
Some people discuss combining them, but there is no established protocol and both are prescription drugs with their own risks and interactions. Any combination is a decision for a licensed clinician, not something to self-assemble.
Does metformin blunt exercise benefits?
There is a real signal worth knowing. A study found metformin reduced some of the mitochondrial adaptations to aerobic exercise training in older adults, which is one reason it is not automatically the right choice for active people.
Are both drugs prescription-only?
Yes. Both rapamycin (sirolimus) and metformin are prescription medicines. Neither should be obtained or used for longevity without a licensed clinician or regulated telehealth provider.
References
- Rapamycin for longevity: the pros, the cons, and future perspectives. Roark KM, Iffland PH. Frontiers in Aging 2025;6:1628187.Peer-reviewed review, cited 31 times.
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Harrison DE et al. Nature 2009;460:392–395.9–14% mouse lifespan extension started mid-life.
- Metformin as a tool to target aging. Barzilai N et al. Cell Metabolism 2016;23(6):1060–1065.Rationale for the TAME (Targeting Aging with Metformin) trial.
- Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Konopka AR et al. Aging Cell 2019;18(1):e12880.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.